673 Results for "

K-Ras

" in MedChemExpress (MCE) Product Catalog:
Products (673)

673 Results for "K-Ras" in MCE Product Catalog:

Cat. No.: HY-161066
Target:  

Ras

Research Areas:  

Cancer

KRAS G13D-IN-1 (Compound 41) is a selective and covalently reversible inhibitor of KRAS G13D (IC50: 0.41 nM). The selectivity for KRAS G13D is 29-fold against KRAS wild type. KRAS G13D-IN-1 is an inhibitor of the GDP state and targets the SWII binding pocket of KRAS G13D. KRAS G13D-IN-1 inhibits KRAS binding to GDP and turns on/off downstream signaling cascades. KRAS G13D-IN-1 can be used in the research of colon cancer .
loading...
    loading...
Cat. No.: HY-18605
CAS No.: 1629267-75-9
Target:  

Ras

Research Areas:  

Cancer

K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.
loading...
    loading...
Cat. No.: HY-130822
CAS No.: 2378261-83-5
Purity:  98.76%
Research Areas:  

Cancer

K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .
loading...
    loading...
Cat. No.: HY-130823
CAS No.: 2378261-85-7
Purity:  99.79%
Research Areas:  

Cancer

K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .
loading...
    loading...
Cat. No.: HY-130707
CAS No.: 2378261-87-9
Research Areas:  

Cancer

K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .
loading...
    loading...
Cat. No.: HY-163594
CAS No.: 3034588-80-9
Target:  

Ras

Research Areas:  

Cancer

K-Ras-IN-58 is a K-RAS inhibitor and shows inhibitory activity against KRASG12D, KRASG12C and KRAS WT. K-Ras-IN-58 inhibits proliferation of cancer cells .
loading...
    loading...
Cat. No.: HY-153412
CAS No.: 2042365-57-9
Target:  

Ras

Research Areas:  

Cancer

KRAS inhibitor-22 (compound FB9/6B9) is a potent inhibitor of K-Ras. KRAS inhibitor-22 targets to Kras 4B(G12D) and (G12C), which can be used for cancer research .
loading...
    loading...
Cat. No.: HY-156363
CAS No.: 905794-70-9
Target:  

Ras

Research Areas:  

Cancer

K-Ras-IN-2 (Compound CHI-000-667) is a K-Ras antagonist, and can be used for tumor research .
loading...
    loading...
Cat. No.: HY-168056
CAS No.: 3043896-37-0
Research Areas:  

Others

KRAS ligand 5 is the target protein ligand for PROTAC K-Ras Degrader-3 (HY-168054). PROTAC K-Ras Degrader-3 can specifically degrade KRAS mutated proteins .
loading...
    loading...
Cat. No.: HY-173329
CAS No.: 3056974-50-3
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-41 is an inhibitor of KRAS with IC50 values of <0.01 μM for KRAS G12D and KRAS G12V. KRAS-IN-41 inhibits RAS mutant cell lines, GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS-IN-41 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-178501
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-45 (Compound 1.019) is a KRAS inhibitor. KRAS-IN-45 can be used for the study of cancers .
loading...
    loading...
Cat. No.: HY-178502
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-46 (Compound 1.013) is a KRAS inhibitor. KRAS-IN-46 can be used for the study of cancers .
loading...
    loading...
Cat. No.: HY-179536
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-49 (compound 7b) is a selective and covalent KRAS G13C inhibitor. KRAS-IN-49 covalently binds to Cys13 of KRAS G13C. KRAS-IN-49 can be used for non-small cell lung cancer (NSCLC) research .
loading...
    loading...
Cat. No.: HY-P11355
CAS No.: 1222762-16-4
Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

KRAS WT Peptide is the normal sequence peptide of the Kirsten rat sarcoma virus (KRAS) gene without oncogenic mutations. KRAS WT Peptide can be used for the study of evaluating the specificity and safety of KRAS-targeted immunotherapies .
loading...
    loading...
Cat. No.: HY-176870
CAS No.: 3033641-67-4
Target:  

Ras

Research Areas:  

Cancer

KRAS-IN-42 (Compound Z1063) is a covalent KRAS G12D mutants inhibitor. KRAS-IN-42 is promising for research of KRAS G12D-mutant cancers (e.g., non-small cell lung cancer, colorectal cancer) .
loading...
    loading...
Cat. No.: HY-151288
CAS No.: 2411786-50-8
Target:  

Ras

Research Areas:  

Cancer

KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor with an IC50 value of <0.01 μM. KRAS inhibitor-21 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-130260
CAS No.: 2374152-69-7
Target:  

Ras

Research Areas:  

Cancer

KRAS inhibitor-4 (compound F12) is a potent KRAS inhibitor and developed as anticancer agents .
loading...
    loading...
Cat. No.: HY-163595
CAS No.: 3024060-23-6
Target:  

Ras

Research Areas:  

Cancer

KRAS G12D-IN-31 is a potent KRAS G12D inhibitor with an IC50 of < 100 nM. KRAS G12D-IN-31 inhibits the proliferation of RAS-dependent cells (KRAS G12C, KRAS G12D, KRAS G12V and KRAS WT). KRAS G12D-IN-31 can be used to study non-small cell lung cancer, gastric cancer, colon cancer, and malignant melanoma .
loading...
    loading...
Cat. No.: HY-135864
CAS No.: 2022986-61-2
Target:  

Ras

Research Areas:  

Cancer

KRAS inhibitor-6 is a potent KRAS G12C inhibitor, extracted from patent WO2017087528A1, compound A .
loading...
    loading...
Cat. No.: HY-146543
CAS No.: 2230873-96-6
Target:  

Ras

Research Areas:  

Cancer

KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC50 of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC50s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers .
loading...
    loading...